US Bancorp DE Sells 615 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

US Bancorp DE trimmed its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 14.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,534 shares of the biopharmaceutical company’s stock after selling 615 shares during the quarter. US Bancorp DE’s holdings in Ultragenyx Pharmaceutical were worth $149,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of RARE. Algert Global LLC lifted its position in shares of Ultragenyx Pharmaceutical by 46.9% in the third quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company’s stock valued at $4,105,000 after buying an additional 23,580 shares during the last quarter. Bamco Inc. NY acquired a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $2,666,000. Principal Financial Group Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after buying an additional 76,150 shares during the last quarter. Cerity Partners LLC acquired a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $1,773,000. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Ultragenyx Pharmaceutical by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock valued at $928,000 after buying an additional 294 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Emil D. Kakkis sold 11,727 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, December 30th. The stock was sold at an average price of $42.23, for a total value of $495,231.21. Following the transaction, the chief executive officer now owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. This trade represents a 0.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Howard Horn sold 1,785 shares of the company’s stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the transaction, the chief financial officer now directly owns 106,169 shares of the company’s stock, valued at approximately $4,289,227.60. The trade was a 1.65 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 136,370 shares of company stock worth $5,751,499. Insiders own 5.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on RARE shares. HC Wainwright reaffirmed a “buy” rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. JPMorgan Chase & Co. cut their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 21st. Piper Sandler lifted their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, January 13th. Canaccord Genuity Group lifted their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. Finally, Wedbush reissued a “neutral” rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average target price of $93.50.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $39.34 on Friday. The stock’s fifty day moving average price is $42.29 and its two-hundred day moving average price is $48.06. Ultragenyx Pharmaceutical Inc. has a one year low of $37.02 and a one year high of $60.37. The firm has a market cap of $3.64 billion, a PE ratio of -6.21 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. Sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.